Introduction {#Sec1}
============

As the first line of host defense, the innate immune system counters viral infection by expressing a number of intrinsic antiviral proteins, triggering the production of interferons (IFNs) and facilitating the activation of adaptive immunity. Intrinsic antiviral proteins, which are constitutively expressed, directly restrict the invasion or replication of viruses. Most intrinsic antiviral proteins can also be induced by IFNs. The expression of IFNs depends strictly on the recognition of pathogens by endosomal Toll-like receptors (TLRs) or cytosolic viral sensors, such as retinoic acid-inducible gene I (RIG-I) and cyclic GMP-AMP synthase. These receptors trigger the transduction of different signals, leading to the induction of type I IFNs (including IFN-α and IFN-β family members) and proinflammatory cytokines. Type I IFNs activate the Janus kinase signal transducer and activator of transcription pathway, and initiate the transcription of IFN-stimulated genes (ISGs). The products of these genes inhibit viral replication, eradicate virus-infected cells and facilitate the activation of antiviral adaptive immunity.^[@CR1],[@CR2]^

TLRs and RIG-I-like receptors (RLRs) detect RNA virus infection. For example, TLR3 recognizes viral double-stranded RNA (dsRNA) released by infected cells and triggers TIR-domain- containing adapter-inducing interferon-β-mediated signaling pathways, whereas TLR7 and TLR8 recognize viral single-stranded RNA and activate MyD88-dependent signaling.^[@CR3],[@CR4]^ The RLRs, such as RIG-I and MDA5, recognize cytoplasmic viral RNA through their C-terminal RNA helicase domains, and then recruit the downstream adapter protein virus-induced signaling adaptor (VISA, also known as MAVS, IPS-1 and Cardif) through their CARD domains.^[@CR5],[@CR6],[@CR7],[@CR8]^ Both TLR- and RLR-triggered signaling cascades activate the downstream kinases TBK1-IKKɛ and TAK1-IKKβ, leading to the activation of interferon regulatory factors (IRFs) and NF-κB. These activated transcription factors collaboratively trigger the transcription of type I IFN genes.^[@CR9],[@CR10]^

Interferon-induced transmembrane (IFITM) proteins are intrinsic antiviral restriction factors. Like other intrinsic factors, the IFITMs can be further induced by IFNs.^[@CR11],[@CR12]^ IFITM3, a member of the IFITM family, has been extensively studied because it plays an important role in preventing endocytosed viral particles from accessing the host cytoplasm. Many viruses are inhibited by IFITM3, including Dengue virus, West Nile virus, Influenza A virus (IAV), flaviviruses, severe acute respiratory syndrome coronavirus and Vesicular stomatitis virus (VSV).^[@CR13],[@CR14],[@CR15]^ These are all enveloped viruses and enter the cell by endocytosis. It has been reported that IFITM3 restricts viruses independently of their receptor usage but is dependent on processes that occur in the endosome. It prevents membrane hemifusion mediated by envelope proteins of IAV and restricts the early steps of IAV replication.^[@CR16]^ It also restricts Human immunodeficiency virus 1 (HIV-1) infection by antagonizing the envelope glycoprotein.^[@CR17]^ IFITM3 restricts the entry of reoviruses, which are nonenveloped viruses, and utilizes endosome-dependent cell entry mechanisms.^[@CR14]^ Although the role of IFITM3 in antiviral immunity has been investigated intensively, here we report our novel observation that IFITM3 negatively regulates the virus-induced production of type I IFNs. Sendai virus (SeV), which fuses with the cell surface, is reportedly not restricted by IFITM3.^[@CR18]^ In this study, we demonstrate that IFITM3 negatively regulates SeV-induced production of type I IFNs by targeting IRF3. Thus, we report a distinctive mechanism of IFITM3 in antiviral immunity.

Materials and methods {#Sec2}
=====================

Constructs {#Sec3}
----------

NF-κB, interferon-sensitive response element (ISRE), IFN-β promoter and IRF1 luciferase reporter plasmids and plasmids for human TBK1, IRF3, VISA and RIG-I have been described.^[@CR19],[@CR20]^ The mammalian expression plasmid for human Flag-tagged IFITM3 was a kind gift from Dr Chen Liang at McGill University and Dr Wentao Qiao at Nankai University. The mammalian expression plasmids for human ATG5 and Beclin1 were provided by Dr Rongjia Zhou at Wuhan University. GFP-Newcastle disease virus (NDV) and GFP-VSV have been previously described.^[@CR21]^

Reagents and antibodies {#Sec4}
-----------------------

Poly(I:C) (Invitrogen, Carlsbad, CA, USA), IFN-γ (Peprotech, Rocky Hill, NJ, USA), IFN-α (Peprotech), TRIzol Reagent (Takara, Dalian, China), Gamma Bind G Plus-Sepharose (Amersham Biosciences, GE Healthcare, Marlborough, MA, USA) and the human IFN-β ELISA kit (PBL, Piscataway, NJ, USA) were purchased from the indicated manufacturers. HEK293 and HeLa cells were obtained from the ATCC. Mouse anti-Flag (Sigma, St Louis, MO, USA), mouse anti-β-actin (Sigma), mouse anti-GFP (Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-LMNB1 (Proteintech, Rosemont, IL, USA), rabbit anti-IRF3 (Santa Cruz Biotechnology), rabbit anti-pIRF3 (CST, Danfoss, MA, USA), rabbit anti-VISA (Bethyl, Montgomery, TX, USA), rabbit anti-TBK1 (Abcam, Cambridge, UK), rabbit anti-pTBK1 (Abcam) and rabbit anti-LC3 (Sigma) antibodies were purchased from the indicated manufacturers. Rabbit and mouse antibodies against IFITM3 were raised against recombinant human IFITM3.

Transfection and reporter assays {#Sec5}
--------------------------------

HEK293 cells or HeLa cells were transfected using the calcium phosphate precipitation method or FuGENE Transfection Reagent (Roche, Basel, Switzerland). The pRL-TK Renilla luciferase reporter plasmid was added to each transfection reaction to normalize for the transfection efficiency. The luciferase assays were performed using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA).^[@CR22]^

Coimmunoprecipitation and immunoblot analyses {#Sec6}
---------------------------------------------

Transfected HEK293 cells from 10-cm dishes were lysed in l ml of Nonidet P-40 lysis buffer (1% Nonidet P-40, 150 mM NaCl, 1 mM EDTA, 20 mM Tris-HCl, pH 7.4--7.5, 10 μg/ml leupeptin, 10 μg/ml aprotinin and 1 mM phenylmethylsulfonyl fluoride). For each immunoprecipitation reaction, 0.9 ml of the cell lysate was incubated with 25 μl of Gamma Bind G Plus-Sepharose and 0.5 μg of antibody for immunoprecipitation at 4 °C for 3 h. The Sepharose beads were intensively washed with lysis buffer containing 0.5 M NaCl. The precipitates were then subjected to SDS-PAGE and immunoblot analysis.

RNA interference (RNAi) constructs {#Sec7}
----------------------------------

The human IFITM3-RNAi constructs were generated using the pSUPER-retro vector (OligoEngine, Seattle, WA, USA) according to the manufacturer's protocol. The target sequences for the human IFITM3 constructs were as follows: \#1, 5′\--3′ and \#2, 5′\--3′. An RNAi construct targeting GFP was used as the control RNAi.

Quantitative real-time PCR (qPCR) {#Sec8}
---------------------------------

Total RNA was extracted from cells with TRIzol Reagent and subjected to real-time PCR analysis. The mRNA levels of specific genes were normalized to that of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA. The gene-specific primer sequences were as follows: GAPDH, 5′\--3′ (forward), 5′\--3′ (reverse); IFNB1, 5′\--3′ (forward), 5′\--3′ (reverse); RANTES, 5′\--3′ (forward), 5′\--3′ (reverse); ISG56, 5′\--3′ (forward), 5′- -3′ (reverse); IRF3, 5′\--3′ (forward), 5′\--3′ (reverse); IFITM3, 5′\--3′(forward), 5′\--3′(reverse).

ELISA {#Sec9}
-----

The supernatants of the cell culture medium were analyzed using a human IFN-β (PBL) ELISA kit following the protocols recommended by the manufacturers.

*In vitro* binding assay {#Sec10}
------------------------

For the glutathione S-transferase (GST) pull-down assay, GST fusion constructs were transformed into bacterial strain BL21. The fusion proteins were induced with 0.1 mM IPTG at 18 °C overnight and purified with Glutathione-Sepharose 4B (GE healthcare) according to the manufacturer's instructions. The purified GST-tagged proteins were then incubated with the HEK293 cell extracts. The protein complex was pulled down with Glutathione-Sepharose 4B beads and then subjected to western blot analysis.

Statistical analysis {#Sec11}
--------------------

Data were statistically analyzed by the Student's *t-*test. *P*-values less than 0.05 were considered statistically significant.

Results {#Sec12}
=======

Overexpression of IFITM3 inhibits SeV-triggered induction of IFN-β {#Sec13}
------------------------------------------------------------------

IFITM3 blocks the infection of many viruses that require endosomal entry pathways.^[@CR14]^ However, whether IFITM3 affects virus-induced production of IFN is still unknown. SeV is not inhibited by IFITM3 (Supplementary Figure [S1a](#MOESM1){ref-type="media"}), possibly because it enters cells by fusing to the cell surface.^[@CR18]^ Thus, we infected HEK293 cells with SeV and performed luciferase assays to identify the role of IFITM3 in RLR-mediated antiviral signaling. Overexpression of IFITM3 inhibited SeV-induced activation of the IFNβ promoter, ISRE and NF-κB in a dose-dependent manner in HEK293 cells (Figure [1a](#Fig1){ref-type="fig"} and Supplementary Figure [S1b](#MOESM1){ref-type="media"}). Similar results were observed in HeLa cells (Supplementary Figure [S1c](#MOESM1){ref-type="media"}), suggesting that the effects of IFITM3 on SeV-triggered antiviral signaling were not cell-type-specific. Overexpression of IFITM3 had no marked effect on IFNγ-triggered activation of the IRF1 reporter in either HEK293 or HeLa cells (Figure [1b](#Fig1){ref-type="fig"} and Supplementary Figure [S1d](#MOESM1){ref-type="media"}) or TLR3 signaling (data not shown), suggesting that IFITM3 specifically inhibits virus-triggered activation of the RLR pathway. Although IFITM1 and IFITM2 have high sequence identities with IFITM3 (61% and 90%, respectively), they had no marked effect on SeV-induced activation of IFNβ and ISRE (Figure [1c](#Fig1){ref-type="fig"}). We extended the analysis by evaluating the transcription of *IFNB1* and its downstream genes. The SeV-triggered or transfected-poly(I:C)-induced transcription of the *IFNB1, RANTES* and *ISG56* genes was inhibited by overexpression of IFITM3 (Figures [1d and e](#Fig1){ref-type="fig"}). SeV or poly(I:C)-induced secretion of IFNβ into the medium was also impaired by overexpression of IFITM3 (Figures [1f and g](#Fig1){ref-type="fig"}). These results suggest that IFITM3 negatively regulates cellular antiviral signaling.Figure 1Overexpression of IFITM3 inhibits virus-triggered induction of IFN-β. (**a** and **c**) HEK293 cells were transfected with the indicated reporters and IFITM3 (**a**) or IFITM1/2 (**c**) expression plasmids (0, 25, 50 ng per 5 × 10^5^ cells). Twenty-four hours after transfection, the cells were infected with SeV or left untreated for 12 h before luciferase assays were performed. (**b**) HEK293 cells were transfected with the IRF1 promoter reporter and the indicated plasmids. The cells were treated with IFN-γ or left untreated before performing the luciferase assays. (**d**--**g**) HEK293 cells were transfected with control or Flag-IFITM3 (100 ng per 10^6^ cells) plasmid for 24 h. The cells were infected with SeV (**d** and **f**) for 10 h or transfected with poly(I:C) (**e** and **g**) followed by real-time PCR (**d** and **e**) or ELISA analysis (**f** and **g**). (**a**--**f**) Graphs show the means±s.d., *n*=3, \**P*\<0.05, \*\**P*\<0.01.

Knockdown of IFITM3 potentiates virus-triggered induction of IFN-β and inhibits viral replication {#Sec14}
-------------------------------------------------------------------------------------------------

To confirm the role of endogenous IFITM3 in RLR-mediated production of type I IFNs, we prepared two RNAi constructs and determined their effects on the knockdown of IFITM3. As shown in Figure [2a](#Fig2){ref-type="fig"}, \#2 IFITM3-RNAi transfection inhibited IFITM3 levels to 10% of the control sample (*P*\<0.01). The \#1 RNAi transfection inhibited IFITM3 levels to 60% of the control sample (Figure [2a](#Fig2){ref-type="fig"}). In the reporter assays, knockdown of IFITM3 by RNAi transfection significantly potentiated SeV-triggered activation of the IFN-β promoter, ISRE and NF-κB, but not IFN-γ-triggered activation of the IRF1 promoter (Figures [2b and c](#Fig2){ref-type="fig"}; Supplementary Figure [S1e](#MOESM1){ref-type="media"}). The degree of potentiation correlated with the knockdown efficiency of the corresponding RNAi construct (Figure [2b](#Fig2){ref-type="fig"} and Supplementary Figure [S1e](#MOESM1){ref-type="media"}). Because the effect of the \#2 RNAi construct was better than that of the \#1 RNAi construct, we selected the IFITM3-RNAi\#2 construct for the experiments described below. Knockdown of IFITM3 by the RNAi construct (IFITM3i) potentiated SeV- and transfected-poly(I:C)-induced transcription of *IFNB1, RANTES* and *ISG56* (Figures [2d and e](#Fig2){ref-type="fig"}), as well as the secretion of IFNβ into the medium (Figures [2f and g](#Fig2){ref-type="fig"}).Figure 2Knockdown of IFITM3 potentiates virus-triggered induction of IFN-β and inhibits viral replication. (**a**) HeLa cells were transfected with the control or indicated RNAi constructs. Cell lysates were analyzed on immunoblots with the indicated antibodies. Graphs show the means±s.d., *n*=3, \**P*\<0.05, \*\**P*\<0.01. (**b** and **c**) HEK293 cells were transfected with the indicated RNAi constructs together with the indicated reporter plasmids. The cells were then infected with SeV (**b**) or IFN-γ (**c**) for 12 h before luciferase assays were performed. (**d**--**g**) HEK293 cells were transfected with the indicated RNAi constructs. Cells were then infected with SeV (**d** and **f**) for 10 h or transfected with poly(I:C) (**e** and **g**) before real-time PCR (**d** and **e**) or ELISA (**f** and **g**) was performed. (**h**) HEK293 cells were transfected with control or IFITM3-RNAi construct for 36 h and then transfected with poly(I:C) for 24 h. The supernatants were collected and applied to Vero cells for 24 h. These Vero cells were infected with GFP-VSV or GFP-NDV (MOI=0.1) for 24 h and visualized by microscopy or analyzed on immunoblots with the indicated antibodies.

Next, we evaluated the effect of IFITM3 on viral replication. The conditioned medium from cultured HEK293 cells, which had been transfected with the IFITM3i construct and poly(I:C), was collected and used to treat Vero cells as previously described.^[@CR23]^ The treated Vero cells were then infected with GFP-VSV or GFP-NDV, and replication of the GFP-labeled viruses was evaluated by direct observation under microscopy. The green fluorescence representing VSV or NDV particles decreased markedly in cells treated with the conditional medium from IFITM3-knockdown cells compared with the control groups (Figure [2h](#Fig2){ref-type="fig"}), suggesting that IFITM3 plays inhibitory roles in virus-triggered induction of IFN-β and subsequently inhibits viral replication.

IFITM3 regulates virus-triggered signaling at the level of IRF3 {#Sec15}
---------------------------------------------------------------

To determine the molecular order of IFITM3 in the virus-triggered signaling pathway, we examined the effects of IFITM3 on the transcription of *IFNB1* mediated by components of the virus-triggered pathway. As shown in Figure [3a](#Fig3){ref-type="fig"}, IFITM3 inhibited the transcription of *IFNB1* induced by overexpression of RIG-I-CARD, VISA, TBK1 and IRF3-5D. Consistent with this finding, knockdown of IFITM3 by RNAi potentiated the transcription of *IFNB1* mediated by overexpression of IRF3 (Figure [3b](#Fig3){ref-type="fig"}). Because activation of the transcription factor IRF3 is a critical event in antiviral signaling, we next determined whether the activation status of IRF3 was affected by IFITM3. SeV-induced dimerization and nuclear translocation of IRF3 were increased in IFITM3-knockdown cells (Figure [3c](#Fig3){ref-type="fig"} and Supplementary Figure [S2a](#MOESM2){ref-type="media"}). The total amount of IRF3 also increased dramatically when IFITM3 was knocked down (Figure [3c](#Fig3){ref-type="fig"}). To confirm this finding, we calculated the ratio of the amount of IRF3 dimer to the total amount of IRF3 by measuring the grayscale values of the bands in Figure [3c](#Fig3){ref-type="fig"}. The results showed that knockdown of IFITM3 enhanced the dimerization of IRF3 (Figure [3d](#Fig3){ref-type="fig"}). However, the transcription level of *IRF3* remained unchanged when IFITM3 was knocked down, suggesting that IFITM3 did not affect IRF3 expression at the level of transcription (Figure [3e](#Fig3){ref-type="fig"}). To determine whether IFITM3 affected the protein levels of IRF3, we evaluated the expression of IRF3 after stimulation with SeV. The protein levels of IRF3 greatly decreased when IFITM3 was overexpressed, whereas knockdown of IFITM3 enhanced the IRF3 levels even without SeV infection (Figures [3f and g](#Fig3){ref-type="fig"}). Consistently, phosphorylation of IRF3 dramatically decreased when IFITM3 was overexpressed and increased when IFITM3 was knocked down (Supplementary Figure [S2b](#MOESM2){ref-type="media"}). In contrast, the expression levels of IFITM3 had no marked effect on the other proteins in this pathway, such as TBK1 or TBK phosphorylation (Figures [3f and g](#Fig3){ref-type="fig"} and Supplementary Figure [S2b](#MOESM2){ref-type="media"}). IFITM1 or IFITM2 had no marked effect on the basal level of IRF3 (Figure [3h](#Fig3){ref-type="fig"}). Collectively, these data suggest that IFITM3 regulates antiviral signaling at the level of IRF3 and participates in the regulation of the basal expression of IRF3.Figure 3IFITM3 regulates virus-triggered signaling at the level of IRF3. (**a**) HEK293 cells were transfected with the indicated expression plasmids together with control or IFITM3 plasmids for 24 h. Real-time PCR was performed 24 h later. (**b**) Stable IFITM3-knockdown HEK293 cells were transfected with the indicated expression plasmids and then analyzed by real-time PCR. Graphs show means±s.d., *n*=3, \**P*\<0.05, \*\**P*\<0.01. (**c** and **d**) Stable IFITM3-knockdown HEK293 cells were infected with SeV or left uninfected for 8 h. The cell lysates were separated by native (top) or SDS (bottom) PAGE and analyzed on immunoblots with the indicated antibodies (**c**). The ratio of the IRF3 dimer to total IRF3 was calculated by measuring the grayscale values of the bands (**d**). (**e**) IRF3 mRNA levels in stable IFITM3-knockdown HEK293 cells after SeV stimulation were measured by real-time PCR. (**f** and **g**) HEK293 cells were transfected with IFITM3 plasmid (**f**) or IFITM3-RNAi construct (**g**). The cells were then infected with SeV and analyzed on immunoblots with the indicated antibodies. The ratio of IRF3 or TBK1 to actin was calculated by measuring the grayscale values of the bands and is shown in the lower panels. (**h**) HEK293 cells were transfected with increased amounts of IFITM1 or IFITM2 plasmids. The endogenous level of IRF3 was then detected by immunoblotting.

IFITM3 associates with IRF3 {#Sec16}
---------------------------

To explore how IFITM3 regulates the expression of IRF3, we performed coimmunoprecipitation to determine whether IFITM3 interacted with IRF3. As shown in Figure [4a](#Fig4){ref-type="fig"}, IFITM3 interacted constitutively with endogenous IRF3, but not VISA, with or without SeV stimulation. Furthermore, IRF3-5A, which is the phosphorylation-deficient mutant of IRF3, was also found to interact with IFITM3 (Figure [4b](#Fig4){ref-type="fig"}), suggesting that the interaction between IFITM3 and IRF3 did not rely on the phosphorylation of IRF3. To further confirm this interaction, we performed an *in vitro* binding assay. Bacterially expressed and affinity-purified GST-IFITM3 fusion protein was incubated with ectopic IRF3 or IRF3-5A-expressing whole-cell extracts. As shown in Figure [4c](#Fig4){ref-type="fig"}, both IRF3 and IRF3-5A were pulled down by GST-IFITM3, suggesting that the interaction between IFITM3 and IRF3 was constitutive and independent of the activation status of IRF3. Consistent with this finding, a confocal immunofluorescence analysis showed that IFITM3 co-localized with IRF3 in the cytoplasm of HeLa cells (Supplementary Figure [S2c](#MOESM2){ref-type="media"}). Domain mapping analysis indicated that the N terminus of IRF3 (amino acids 1--140) was responsible for its interaction with IFITM3 (Figure [4d](#Fig4){ref-type="fig"}). Because IFITM3 was induced by IFNs, we analyzed the kinetic pattern of IFITM3 and IRF3. The expression of IFITM3 was induced while the expression of IRF3 was decreased following IFNα or poly(I:C) transfection treatment (Figure [4e](#Fig4){ref-type="fig"}). These data suggest that IFITM3 associates with IRF3 and possibly mediates the degradation of IRF3.Figure 4IFITM3 Associates with IRF3. (**a**) HEK293 cells were transfected with Flag-IFITM3 plasmid and infected with SeV. The cell lysates were tested by coimmunoprecipitation and analyzed on immunoblots with the indicated antibodies. (**b**) HEK293 cells were transfected with HA-IFITM3 and Flag-IRF3 or Flag-IRF3-5A plasmid. The cell lysates were coimmunoprecipitated and analyzed by immunoblots with the indicated antibodies. (**c**) Glutathione-Sepharose beads coupled to GST-IFITM3 were incubated with HEK293 cell extracts expressing Flag-IRF3 or Flag-IRF3-5A. Proteins bound to the beads were analyzed by western blotting. The experiment was repeated twice with comparable results. (**d**) Mapping of the minimal interaction domains between IRF3 and IFITM3. HEK293 cells (1 × 10^7^) were transfected with the indicated plasmids. Coimmunoprecipitation and immunoblots were performed. (**e**) HeLa cells were treated with IFNα (upper panel) or transfected with poly(I:C) (lower panel) for the indicated times. Cell lysates were then applied to the immunoblot.

IFITM3 mediates autophagic degradation of IRF3 {#Sec17}
----------------------------------------------

IRF3 degradation is mediated by proteasomal degradation and/or autophagy.^[@CR24],[@CR25],[@CR26]^ To investigate the role of IFITM3 in IRF3 degradation, we prepared an RNAi-off-target IFITM3 mutant (Flag-IFITM3-M) with three nucleotide nonsense mutations in the target sequence of the IFITM3-RNAi construct. As shown in Supplementary Figure [S3a](#MOESM3){ref-type="media"}, the IFITM3-RNAi construct could inhibit the expression of Flag-IFITM3 but not Flag-IFITM3-M. Next, we reconstituted the expression of IFITM3 in stable IFITM3-knockdown 293 cells by overexpressing Flag-IFITM3-M, and treated the cells with the proteasome inhibitor MG132 or the autophagy inhibitor 3-MA. MG132 treatment had little effect on the degradation of IRF3 caused by overexpression of Flag-IFITM3-M (Figure [5a](#Fig5){ref-type="fig"}). However, 3-MA treatment could inhibit the degradation of IRF3 caused by overexpression of Flag-IFITM3-M (Figure [5a](#Fig5){ref-type="fig"}), suggesting that the IFITM3-mediated degradation of IRF3 was autophagy-dependent but not proteasome-dependent. To confirm this finding, we first assessed whether IRF3 was degraded through autophagy in our system. Silencing autophagy-related 7 (ATG7), which is a key factor during the synthesis of the autophagosome precursor, leads to the inhibition of autophagy.^[@CR27]^ Mouse atg7-deficient (atg7^−/−^) MEF cells and control wild-type (WT) cells were treated with cycloheximide (CHX), an inhibitor of new protein synthesis. Immunoblotting analysis showed that the level of IRF3 was higher in Atg7^−/−^ cells than in WT cells after treatment with CHX (Supplementary Figure [S3b](#MOESM3){ref-type="media"}), confirming previous reports that autophagy is one of the turnover mechanisms of IRF3.^[@CR26]^ It has been reported that overexpression of IFITM3 can induce autophagy, including LC3 puncta and lipidation.^[@CR28],[@CR29]^ Consistent with this finding, IFITM3 dose-dependently promoted the transformation of type I LC3 to type II LC3, which is an indicator of enhanced autophagy (Figure [5b](#Fig5){ref-type="fig"}). A confocal immunofluorescence analysis showed that IFITM3 co-localized with autophagic components such as LC3, ATG5 and Beclin1 (Figures [5c and d](#Fig5){ref-type="fig"}). Moreover, IFITM3 or IRF3 interacted with LC3 and Beclin1 (Figure [5e](#Fig5){ref-type="fig"}), suggesting that LC3 and Beclin1 are involved in the process of IFITM3 mediating the autophagic degradation of IRF3. Overexpression of IFITM3 changed the subcellular location of IRF3 from a disperse distribution in the cytosol to specific organelle autophagosomes, as indicated by LC3-GFP (Figure [5f](#Fig5){ref-type="fig"}), suggesting that IFITM3 mediates the autophagic degradation of IRF3. Furthermore, viral infection induced the majority of IRF3 to translocate to the nucleus, but a portion of IRF3 co-localized with LC3, suggesting that SeV could indeed induce the translocation of cytosolic IRF3 into autophagosomes (Figure [5f](#Fig5){ref-type="fig"}). In HEK293 cells treated with CHX, IRF3 was degraded much more slowly when IFITM3 was silenced in comparison to the control cells (Figure [5g](#Fig5){ref-type="fig"}), suggesting that IFITM3-mediated autophagic degradation of IRF3 was critical for the turnover of IRF3.Figure 5IFITM3 mediates autophagic degradation of IRF3. (**a**) Stable IFITM3-knockdown HEK293 cells were transfected with the indicated plasmids and treated with 3-MA or MG132 for 6 h before an immunoblot analysis was performed. (**b**) HEK293 cells were transfected with increasing amounts of Flag-IFITM3 and analyzed on immunoblots with the indicated antibodies. (**c** and **d**) HeLa cells transfected with the indicated plasmids were infected with SeV for 12 h or left untreated and then analyzed under immunofluorescence microscopy. (**e**) HEK293 cells were transfected with the indicated plasmids and applied to the coimmunoprecipitation and immunoblot experiments. (**f**) HeLa cells were transfected with Flag-IFITM3 and LC3-GFP plasmids, or infected with SeV. Immunofluorescence assays were performed using anti-IRF3 antibody as the primary antibody. (**g**) Stable IFITM3-knockdown HEK293 cells were infected with SeV and treated with CHX for the indicated times before immunoblot analysis was performed (left panel). The expression levels of IRF3 and actin were semi-quantified by measuring the grayscales of the bands on the western blots. The normalized expression of IRF3 is shown in the line chart (right panel).

Discussion {#Sec18}
==========

IFITM3 has been extensively studied as a restriction factor that confers broad resistance to viral infection.^[@CR13],[@CR14]^ The enveloped and nonenveloped viruses that are restricted by IFITM3 utilize an endosomal entry mechanism.^[@CR30],[@CR31]^ IFITM3 restricts their replication by blocking virus-endosome fusion.^[@CR29],[@CR32]^ A possible underlying mechanism is that IFITM3 induces the accumulation of cholesterol in multi-vesicular bodies and in late endosomes, thus impairing the membrane fusion of intraluminal virion-containing vesicles and endosomes.^[@CR33]^ IFITM3 is also strongly retained in resident memory CD8^+^ T cells to facilitate cell survival and enhance cell resistance to infection with influenza viruses.^[@CR34]^

Here we report a novel role of IFITM3 in regulating the virus-induced production of type I IFNs. Using SeV or the dsRNA analog poly(I:C) as the agonist, we have shown that overexpression of IFITM3, but not IFITM1 or IFITM2, inhibits cytosolic-RNA-induced activation of the IFN-β promoter and the transcription of *IFNB1* and its downstream antiviral genes, whereas the knockdown of IFITM3 has the opposite effects. Knockdown of IFITM3 enhances the dimerization and nuclear translocation of IRF3, and it promotes the antiviral signaling pathway against viral replication. These results suggest that IFITM3, the expression of which is enhanced by viral infection and type I IFNs, regulates the virus-triggered antiviral response in a negative-feedback manner. Many ISGs not only block viral replication during different phases of the viral replication cycle, but they also regulate the production of IFNs to maintain suitable antiviral responses. For example, ISG56 negatively regulates cellular antiviral responses by disrupting the interactions between mediator of IRF3 activation and VISA or TBK1.^[@CR35]^ Type I IFN leads to the induction of RBCK1, which can induce the subsequent degradation of IRF3.^[@CR36]^ PCBP2, another ISG, acts as a scaffold to facilitate AIP4-mediated degradation of VISA, which is a critical mechanism in the negative regulation of RLR signaling and is also apparent in Figure [4a](#Fig4){ref-type="fig"}.^[@CR37]^ By contrast, DDX60 enhances RLR-mediated production of IFNs by binding to RIG-I and promoting the binding of RIG-I to dsRNA. ISG15 regulates type I IFN signaling by modulating the ISGylation of RIG-I and IRF3.^[@CR38],[@CR39],[@CR40]^ Our study adds IFITM3 to the ISGs that negatively regulate virus-induced induction of type I IFNs while simultaneously inhibiting viral replication. As is well known, immoderate immune responses lead to pathological tissue damage and even induce autoimmune reactions. The inhibitory effects of IFITM3 on both IFN production and viral replication are undoubtedly important for maintaining a suitable level of innate antiviral responses.

The role of IFITM3 in restricting viruses is considered to be closely related to its cellular localization. IFITM3 partially localizes to acidic compartments, including late endosomes expressing Rab5 and Rab7, lysosomes expressing LAMP1, and autolysosomes expressing LC3 and CD63.^[@CR28],[@CR29]^ IFITM3 restriction of SARS-CoV is circumvented when trypsin digestion is used to trigger membrane fusion at or near the plasma membrane rather than within the acidic cellular compartment.^[@CR32]^ In this study, we found that the role of IFITM3 in regulating IFN signaling is also closely related to its cellular localization. We observed that overexpression of IFITM3 led to an increase in LC3 transformation and the formation of LC3 puncta (Figures [5b and f](#Fig5){ref-type="fig"}). Based on the substantial increase in IRF3 when IFITM3 is depleted (Figure [3c](#Fig3){ref-type="fig"}), we demonstrated that IRF3 and IFITM3 interact constitutively with one another and co-localize with the same cellular autophagosome compartments (Figures [4a--d](#Fig4){ref-type="fig"} and Supplementary Figure [S2c](#MOESM2){ref-type="media"}). Because the autophagy inhibitor 3-MA rescued the degradation of IRF3 caused by IFITM3 (Figure [5a](#Fig5){ref-type="fig"}), we confirmed that autophagy is one mechanism of IRF3 homeostasis and that overexpression of IFITM3 enhances the process of autophagy, as evidenced by the transformation of LC3 from type I to type II. Finally, but importantly, we have provided evidence that IRF3 is concentrated in autolysosomes expressing LC3 when IFITM3 is overexpressed (Figure [5f](#Fig5){ref-type="fig"}). Upon stimulation by viruses, high levels of IFITM3, induced by IFNs, enhance the degradation of IRF3 by autophagy and thus regulate antiviral immune responses via a negative-feedback mechanism. Although in this study we have shown that IFITM3 negatively regulates the activation of NF-κB (Supplementary Figures [S1b and S1e](#MOESM1){ref-type="media"}), it is still unclear whether this function is related to autophagy, necessitating further study.

In summary, our study reveals a novel function of IFITM3 in antiviral immunity. IFITM3 not only restricts many viruses but also negatively regulates type I IFN signaling by enhancing the autophagic degradation of IRF3. Our findings demonstrate a previously undescribed role of IFITM3 in regulating cellular antiviral responses.
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